| Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ... New England Journal of Medicine 379 (1), 11-21, 2018 | 2144 | 2018 |
| Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1115 | 2018 |
| In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration K Suzuki, Y Tsunekawa, R Hernandez-Benitez, J Wu, J Zhu, EJ Kim, ... Nature 540 (7631), 144-149, 2016 | 1099 | 2016 |
| Sirolimus (RAPAMYCIN)-BASED therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: 1, 2 CG Groth, L Bäckman, JM Morales, R Calne, H Kreis, P Lang, JL Touraine, ... Transplantation 67 (7), 1036-1042, 1999 | 1086 | 1999 |
| Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial T Coelho, LF Maia, AM da Silva, MW Cruz, V Planté-Bordeneuve, ... Neurology 79 (8), 785-792, 2012 | 823 | 2012 |
| High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients F Maduell, F Moreso, M Pons, R Ramos, J Mora-Macià, J Carreras, ... Journal of the American Society of Nephrology: JASN 24 (3), 487, 2013 | 814 | 2013 |
| Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ... American Journal of Transplantation 7 (6), 1506-1514, 2007 | 706 | 2007 |
| Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft Recipients12 H Kreis, JM Cisterne, W Land, L Wramner, JP Squifflet, D Abramowicz, ... Transplantation 69 (7), 1252-1260, 2000 | 684 | 2000 |
| In vivo amelioration of age-associated hallmarks by partial reprogramming A Ocampo, P Reddy, P Martinez-Redondo, A Platero-Luengo, F Hatanaka, ... Cell 167 (7), 1719-1733. e12, 2016 | 682 | 2016 |
| Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial FP Schena, MD Pascoe, J Alberu, M del Carmen Rial, R Oberbauer, ... Transplantation 87 (2), 233-242, 2009 | 671 | 2009 |
| Sirolimus and secondary skin-cancer prevention in kidney transplantation S Euvrard, E Morelon, L Rostaing, E Goffin, A Brocard, I Tromme, ... New England Journal of Medicine 367 (4), 329-339, 2012 | 609 | 2012 |
| Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation JM Campistol, J Eris, R Oberbauer, P Friend, B Hutchison, JM Morales, ... Journal of the American Society of Nephrology 17 (2), 581-589, 2006 | 592 | 2006 |
| Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) A Durrbach, JM Pestana, T Pearson, F Vincenti, VD Garcia, J Campistol, ... American Journal of Transplantation 10 (3), 547-557, 2010 | 578 | 2010 |
| Interspecies chimerism with mammalian pluripotent stem cells J Wu, A Platero-Luengo, M Sakurai, A Sugawara, MA Gil, T Yamauchi, ... Cell 168 (3), 473-486. e15, 2017 | 512 | 2017 |
| Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review A Gutierrez-Dalmau, JM Campistol Drugs 67, 1167-1198, 2007 | 440 | 2007 |
| In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui, T Yamauchi, ... Cell 171 (7), 1495-1507. e15, 2017 | 405 | 2017 |
| Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells Y Xia, E Nivet, I Sancho-Martinez, T Gallegos, K Suzuki, D Okamura, ... Nature cell biology 15 (12), 1507-1515, 2013 | 347 | 2013 |
| Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma12 JM Campistol, A Gutierrez-Dalmau, JV Torregrosa Transplantation 77 (5), 760-762, 2004 | 347 | 2004 |
| Case report of COVID‐19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? E Guillen, GJ Pineiro, I Revuelta, D Rodriguez, M Bodro, A Moreno, ... American Journal of Transplantation 20 (7), 1875-1878, 2020 | 317 | 2020 |
| Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study OB Suhr, T Coelho, J Buades, J Pouget, I Conceicao, J Berk, H Schmidt, ... Orphanet journal of rare diseases 10 (1), 1-9, 2015 | 306 | 2015 |
